Full Press Release Details
MENLO PARK, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today announced the presentation of new data at the Annual Meeting of the Endocrine Society (ENDO), taking place in New Orleans, Louisiana from March 23 – 26, 2019.
“We look forward to presenting new findings concerning cortisol modulation in patients with hypercortisolism,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. “We are also excited to present the design of the Phase 3 trial (entitled “GRACE”) of our selective cortisol modulator, relacorilant.”
| Sunday, March 24, 2019 | |
| Poster No. SUN-451 A Randomized-Withdrawal, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Selective Glucocorticoid Receptor Antagonist, Relacorilant, in Patients with Cushing Syndrome (GRACE Study) | R. Auchus J. Findling A. Moraitis |
| Poster No. SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas | M. Terzolo D. Iacuaniello A. Pia P. Adriano A. Moraitis R. Pivonello |
| Poster No. SUN-383 Sustained Clinical Improvement after Discontinuation of Mifepristone: Unexpected Remission of Hypercortisolism | R. Anderson N. Pesa A. Kassar |
| Poster No. SUN-460 Anticipating Hypokalemia in Patients With ACTH- Dependent Cushing Syndrome Treated With Mifepristone: Utilization of Cortisol and ACTH Levels to Identify At-Risk Patients | A. Moraitis D. Nguyen |
Hypercortisolism, often referred to as Cushing’s syndrome, is caused by excessive activity of the hormone cortisol. Endogenous Cushing’s syndrome is an orphan disease that most often affects adults aged 20-50. In the United States, an estimated 20,000 patients have Cushing’s syndrome, with about 3,000 new patients being diagnosed each year. Symptoms vary, but most people experience one or more of the following manifestations: high blood sugar, diabetes, high blood pressure, upper-body obesity, rounded face, increased fat around the neck, thinning arms and legs, severe fatigue and weak muscles. Irritability, anxiety, cognitive disturbances and depression are also common. Cushing’s syndrome can affect every organ system in the body and can be lethal if not treated effectively.
About Corcept Therapeutics Incorporated
Corcept is a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Corcept’s approved product, Korlym®, was the first FDA-approved treatment for patients with Cushing’s syndrome. Korlym modulates the activity of cortisol at the glucocorticoid receptor, one of the two receptors to which cortisol binds. The company has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and in the use of cortisol modulators, including Korlym, to treat a wide variety of serious disorders.
Christopher S. James, MD
Director, Investor Relations
Corcept Therapeutics